ImmunityBio (IBRX) Expected to Announce Earnings on Tuesday

Key Points

• ImmunityBio is set to release its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($0.10) per share and revenue of $21.95 million.
• The company's stock is currently trading at $2.39, with a market capitalization of $2.11 billion and a significant price-to-earnings ratio of -4.11.
• Several analysts have reaffirmed a "buy" rating for ImmunityBio, with price targets ranging from $5.00 to $30.00, indicating a generally optimistic outlook on the stock's performance.

ImmunityBio (NASDAQ:IBRX - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect ImmunityBio to post earnings of ($0.10) per share and revenue of $21.95 million for the quarter.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The company had revenue of $26.43 million for the quarter, compared to the consensus estimate of $21.95 million. On average, analysts expect ImmunityBio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ImmunityBio Trading Up 0.2%

ImmunityBio stock traded up $0.01 during trading hours on Friday, reaching $2.42. 561,450 shares of the company were exchanged, compared to its average volume of 7,628,848. ImmunityBio has a 12 month low of $1.83 and a 12 month high of $7.48. The stock has a 50-day moving average of $2.78 and a 200 day moving average of $2.83. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of -5.03 and a beta of 0.12.

Wall Street Analyst Weigh In

IBRX has been the subject of a number of recent analyst reports. D. Boral Capital restated a "buy" rating and set a $30.00 price target on shares of ImmunityBio in a report on Tuesday. Piper Sandler raised ImmunityBio from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $4.25 to $5.00 in a research report on Tuesday, May 20th. Finally, HC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of ImmunityBio in a research report on Wednesday, June 4th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $12.25.

Institutional Trading of ImmunityBio

An institutional investor recently raised its position in ImmunityBio stock. AQR Capital Management LLC grew its holdings in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 193.4% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 44,448 shares of the company's stock after buying an additional 29,297 shares during the quarter. AQR Capital Management LLC's holdings in ImmunityBio were worth $134,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.58% of the company's stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.